Connect with us

Business

CBD No Better Than Placebo For Cancer Symptoms: Are We Back At It Again?

Published

on

Can you really conclude from one study that CBD isolate is not effective in relieving “a myriad of symptoms” in advanced cancer?

A study that was published last month in the Journal of Clinical Oncology found that cannabidiol (CBD) is no better than placebo in relieving symptoms of end stage cancer. This was a double blind and placebo-controlled study that was conducted by Mater Research in collaboration with the University of Queensland.

Before we even dive into the details of the study, one generally wonders how a single compound in cannabis offered at the same dosage is supposed to relieve a myriad of symptoms. That more or less sounds like machine gun medicine, something that the medical cannabis community has often picked issue with.

cancer treatment
Photo by Tima Miroshnichenko via Pexels

Details of the Study

The study involved 144 participants, all who were  receiving palliative treatment for advanced cancer. The participants received either pure CBD or placebo for a duration of 28 days. The researchers investigated the effects of CBD in relieving general distress, pain, anxiety, and depression. They also monitored adverse effects.

https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-4007899114954491&output=html&h=280&slotname=7947877161&adk=1136884943&adf=3886891445&pi=t.ma~as.7947877161&w=696&fwrn=4&fwrnh=100&lmt=1670695184&rafmt=1&format=696×280&url=https%3A%2F%2Fthefreshtoast.com%2Fcbd%2Fcbd-no-better-than-placebo-for-cancer-symptoms-are-we-back-at-it-again%2F&fwr=0&fwrattr=true&rpe=1&resp_fmts=3&wgl=1&adsid=ChAIgPnQnAYQtar7kbWB6uxZEj0AstyMTY0FpYzHZgzY8dwV1HTmZzJtU0yk5eF0DqB5SsDZoFfp1Fh3QlHVZq0ANTXECbVXX0TxfJxALavL&uach=WyJXaW5kb3dzIiwiMTAuMC4wIiwieDg2IiwiIiwiMTA4LjAuNTM1OS45OSIsW10sZmFsc2UsbnVsbCwiNjQiLFtbIk5vdD9BX0JyYW5kIiwiOC4wLjAuMCJdLFsiQ2hyb21pdW0iLCIxMDguMC41MzU5Ljk5Il0sWyJHb29nbGUgQ2hyb21lIiwiMTA4LjAuNTM1OS45OSJdXSxmYWxzZV0.&dt=1670695162229&bpp=28&bdt=1464&idt=568&shv=r20221206&mjsv=m202211300101&ptt=9&saldr=aa&abxe=1&cookie=ID%3Ddffa619281ab3ea4-223edf950bd80014%3AT%3D1667444252%3ART%3D1667444252%3AS%3DALNI_MYrUj-fjMeBiFd9cwKZEnN0E4jQIA&gpic=UID%3D0000089b1050f759%3AT%3D1667444252%3ART%3D1670693621%3AS%3DALNI_Ma20b1YVis8sAv15JCnZHFGxc0UEw&prev_fmts=0x0%2C696x280&nras=1&correlator=2934467881059&frm=20&pv=1&ga_vid=1999515006.1667444247&ga_sid=1670695162&ga_hid=406072514&ga_fc=1&u_tz=330&u_his=1&u_h=686&u_w=1220&u_ah=648&u_aw=1220&u_cd=24&u_sd=1.575&dmc=8&adx=68&ady=2701&biw=1204&bih=491&scr_x=0&scr_y=743&eid=44759876%2C44759927%2C44759842%2C31071199%2C44779794&oid=2&psts=AMjMPc0iMMx3pKp17WoYoeN6vP3viLcx005kMBUhdJv1d5Hf6yoLvPJCQD71sL1CM_o2s2E99nmb85f1dhQfVQ&pvsid=847542331889717&tmod=35216950&uas=3&nvt=1&ref=https%3A%2F%2Fthefreshtoast.com%2F&eae=0&fc=1920&brdim=0%2C0%2C0%2C0%2C1220%2C0%2C1220%2C648%2C1220%2C491&vis=1&rsz=%7C%7Coebr%7C&abl=CS&pfx=0&fu=128&bc=31&ifi=3&uci=a!3&btvi=2&fsb=1&xpc=5ZfK0ZCTv9&p=https%3A//thefreshtoast.com&dtd=21847

All the parameters were observed and recorded at 14 days and at 28 days. The results showed no significant difference in symptom improvement in patients who received CBD compared to those who received placebo. Also, adverse effects reported were not related to either interventions (CBD or placebo). A conclusion was made that “CBD may not add value in reducing symptoms for patients with advanced cancer beyond standard palliative care.” And it seemed that the researchers were not surprised by this finding.

“The best way to describe the uptake of medicinal cannabis following its legalization was as a social phenomenon — everyone wanted it, but there was little evidence to guide its usage,” said lead researcher Professor Hardy.

Issue 1: Dosage of CBD Offered for Palliative Care

The participants were offered titrations of CBD oil or placebo from 50mg/day to 600mg/day. In comparison, CBD oil for epilepsy (Epidiolex) is offered at a starting dose of 5 mg/kg/day (350mg for a 70kg man) to 20 mg/kg/day (1,400mg for a 70kg man). This is not to say that the CBD dose offered was too low. A different study showed that a dose of 300mg/day of oral CBD was effective in treating chemotherapy-induced peripheral neuropathy.

However, one wonders whether higher doses of CBD could have worked better for some symptoms. Would it not have been more effective to assess one condition at a time and rule out the potential of different doses of CBD isolate in offering relief? Or can you conclude from one study that CBD isolate is not effective in relieving “a myriad of symptoms” in advanced cancer?

Here’s the thing. Surprisingly, 36% of the study participants opted to purchase the CBD treatment in spite of being aware of the results and even being convinced that they were part of the active (CBD) arm of the study. There are two possible explanations for this: general optimism in spite of lack of evidence (as cited by the researchers) or the participants actually experienced an improved sense of wellbeing.

Dr. Grinspoon, a well respected thought leader in medical cannabis, has previously reported that “people almost exclusively talk about their quality of life getting better when using cannabis as compared to opiates.”

But dosage is the smaller issue here.

seniors marijuana
Photo by Westend61/Getty Images

Issue 2: CBD Isolate Versus Full Spectrum CBD

Cannabis is made up of hundreds of bioactive molecules, with CBD and THC being the most popular. These compounds act together synergistically to enhance the therapeutic benefits in what has been described as the entourage mechanism. For example, when it comes to managing pain or nausea and vomiting, studies have shown that a combination of THC and CBD is more effective than an isolate of each compound on its own.

While it is believed that THC has stronger analgesic properties, CBD helps to offset some of the negative effects of THC. In addition, terpenes also play a key role in unleashing the true potential of medical cannabis. Therefore, when looking at a broad range of cancer symptoms, it would be unfair to overlook the benefits that are offered through the entourage mechanism.

While CBD as an isolate may offer great relief for epilepsy, it may require additional compounds or substitutes to address other cancer symptoms.

Is CBD Any Good For Cancer?

That’s a hard question to answer from any one study. Some studies have demonstrated anti-tumor properties of CBD in some cancers but not others. When it comes to symptoms of advanced cancer, this is best looked at on a case-by-case basis.

While it may be true that there might be an “over-optimism” about medical cannabis, there also could be some “over-pessimism” from a sector of the medical community. And as the saying goes, if all you have is a hammer, everything you see will look like a nail.

Source: https://thefreshtoast.com/cbd/cbd-no-better-than-placebo-for-cancer-symptoms-are-we-back-at-it-again/

Business

Alleged Crores Pharma Scam Mastermind Arrested from Surat

Published

on

By

After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.

Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.

Fake Business Deals and Dishonoured Cheques Used in Fraud

Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.

In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”

Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.

Multiple Identities and Repeated Fraud Pattern

Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.

Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.

Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.

Multi-State Surveillance Leads to Arrest in Surat

A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.

Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.

Growing Threat of Corporate Identity Fraud

The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.

Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.

Experts Urge Stronger Due Diligence in High-Value Transactions

Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.

Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.

Continue Reading

Business

EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices

Published

on

By

A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.

Investigation Under Digital Markets Act Gains Momentum

The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.

Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.

Industry Groups Demand Swift Action

Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.

Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.

In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.

Google Denies Allegations

Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.

However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.

Potential Billion-Euro Penalties

If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.

Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.

Wider Implications for Big Tech

The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.

A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.

As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.

Continue Reading

AI & Technology

Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations

Published

on

By

Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).

The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.

Trial Push Despite Multi-Million Euro Settlement

The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.

Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.

A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.

Allegations of VAT Evasion Through Marketplace Sellers

At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.

Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.

Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.

Italian Government Named as Affected Party

In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.

Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.

Multiple Investigations Add to Pressure

The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.

Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.

In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.

Amazon Denies Allegations

Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.

Broader Impact on Europe’s Digital Economy

If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.

With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News